COMBIVENT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIVENT RESPIMAT is a fixed-dose combination inhaler containing ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 agonist) for treating chronic obstructive pulmonary disease (COPD). It combines two distinct bronchodilator mechanisms to produce greater airway relaxation than either agent alone. The dual mechanism targets both muscarinic receptors and beta-2 adrenergic receptors in the lung.
LOE Approaching
As LOE approaches, the brand team is likely transitioning from growth initiatives to life-cycle management and retention strategies; team size may be optimized for maintenance phase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Ventilator Adapters for Combivent Respimat
Started Oct 2013
11 enrolled
Pulmonary Disease, Chronic Obstructive
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
Started Nov 2009
470 enrolled
Pulmonary Disease, Chronic Obstructive
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
Started Dec 2008
226 enrolled
Asthma
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
Started Nov 2006
1,480 enrolled
Pulmonary Disease, Chronic Obstructive
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
Started Oct 2006
327 enrolled
Pulmonary Disease, Chronic Obstructive
Worked on COMBIVENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.